Levetiracetam and brivaracetam: a review of evidence from clinical trials and clinical experience

Bernhard J Steinhoff, Anke M Staack, Bernhard J Steinhoff, Anke M Staack

Abstract

Until the early 1990s, a limited number of antiepileptic drugs (AEDs) were available. Since then, a large variety of new AEDs have been developed and introduced, several of them offering new modes of action. One of these new AED families is described and reviewed in this article. Levetiracetam (LEV) and brivaracetam (BRV) are pyrrolidone derivate compounds binding at the presynaptic SV2A receptor site and are thus representative of AEDs with a unique mode of action. LEV was extensively investigated in randomized controlled trials and has a very promising efficacy both in focal and generalized epilepsies. Its pharmacokinetic profile is favorable and LEV does not undergo clinically relevant interactions. Adverse reactions comprise mainly asthenia, somnolence, and behavioral symptoms. It has now been established as a first-line antiepileptic drug. BRV has been recently introduced as an adjunct antiepileptic drug in focal epilepsy with a similarly promising pharmacokinetic profile and possibly increased tolerability concerning psychiatric adverse events. This review summarizes the essential preclinical and clinical data of LEV and BRV that is currently available and includes the experiences at a large tertiary referral epilepsy center.

Keywords: SV2A receptor; brivaracetam; drug therapy; epilepsy; levetiracetam.

Conflict of interest statement

Conflict of interest statement: Bernhard J Steinhoff has received speaker’s honoraria from Al-Jazeera, Desitin, Eisai, GW Pharmaceuticals, Hikma, Novartis, Sandoz, and UCB and has served as a paid consultant for Arvelle, Bial, B. Braun, Desitin, Eisai, GW Pharmaceuticals, and UCB. Anke M. Staack has received speaker’s honoraria from Eisai, Desitin, and UCB.

References

    1. Steinhoff BJ. Antiepileptic therapy with bromides - historical and actual importance. J Hist Neurosci 1992; 1: 119–123.
    1. Steinhoff BJ. The AMPA receptor antagonist perampanel in the adjunctive treatment of partial-onset seizures: clinical trial evidence and experience. Ther Adv Neurol Disord 2015; 8: 137–147.
    1. MacDonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995; 36(Suppl. 2): S2–S12.
    1. Löscher W, Hönack D. Profile of ucb L059, a novel anticonvulsant drug, in models of partial and generalized epilepsy in mice and rats. Eur J Pharmacol 1993; 232: 147–158.
    1. Milovanovic JR, Jankovic SM, Pejcic A, et al. Evaluation of brivaracetam: a new drug to treat epilepsy. Expert Opin Pharmacother 2017; 18: 1381–1389.
    1. Genton P, Van Vleymen B. Piracetam and levetiracetam: close structural similarities but different pharmacological and clinical profiles. Epileptic Disord 2000; 2: 99–105.
    1. Klitgaard H, Matagne A, Nicolas JM, et al. Brivaracetam: rationale for the discovery and preclinical profile of SV2A ligand for epilepsy treatment. Epilepsia 2016; 57: 538–548.
    1. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drugs Rev 2005; 11: 169–182.
    1. Giurgea C, Salama M. Nootropic drugs. Progress Neuropsychopharmacol 1977; 1: 235–247.
    1. Klitgaard H, Verdru P. Levetiracetam: the first SV2A ligand for the treatment of epilepsy. Expert Opin Drug Discov 2007; 2: 1537–1545.
    1. Obeso JA, Artieda J, Luquin MR, et al. Antimyoclonic action of piracetam. Clin Neuropharmacol 1986; 9: 58–64.
    1. Paulus W, Ried S, Stodieck SRG, et al. Abolition of photoparoxysmal response in progressive myoclonus epilepsy. Eur Neurol 1991; 31: 388–390.
    1. Brown P, Steiger MJ, Thompson PD, et al. Effectiveness of piracetam in cortical myoclonus. Mov Disord 1993; 8: 63–68.
    1. Winblad B. Piracetam: a review of pharmacological properties and clinical uses. CNS Drugs Rev 2005;11:169–182.
    1. Kasteleijn-Nolst Trenité DG, Marescaux C, Stodieck SRG, et al. Photosensitive epilepsy: a model to study the effects of antiepileptic drugs. Evaluation of the piracetam analogue, levetiracetam. Epilepsy Res 1996; 25: 225–230.
    1. Genton P, Gélisse P. Antimyoclonic effect of levetiracetam. Epileptic Disord 2000; 2: 209–212.
    1. Frucht SJ, Louis ED, Chuang C, et al. A pilot tolerability and efficacy study of levetiracetam in patients with chronic myoclonus. Neurology 2001; 57: 1112–1114.
    1. Krauss GL, Bergin A, Kramer RE, et al. Suppression of post-hypoxic and post-encephalitic myoclonus with levetiracetam. Neurology 2001; 56: 411–412.
    1. Patsalos PN. The pharmacokinetic characteristics of levetiracetam. Methods Find Exp Clin Pharmacol 2003; 25: 123–129.
    1. De Smedt T, Raedt R, Vonck K, et al. Levetiracetam: part II, the clinical profile of a novel anticonvulsant drug. CNS Drug Rev 2007; 13: 57–78.
    1. Patsalos PN. Clinical pharmacokinetics of levetiracetam. Clin Pharmacokinet 2004; 43: 707–724.
    1. Patsalos PN. Pharmacokinetic profile of levetiracetam: toward ideal characteristics. Pharmacol Ther 2000; 85: 77–85.
    1. Sohn YH, Kaelin-Lang A, Jung HY, et al. Effect of levetiracetam on human corticospinal excitability. Neurology 2001; 57: 858–863.
    1. Ulloa CM, Towfigh A, Safdieh J. Review of levetiracetam, with a focus on the extended release formulation, as adjuvant therapy in controlling partial-onset seizures. Neuropsychiatr Dis Treat 2009; 5: 467–476.
    1. Anderson GD, Santo RF. Modified-release formulations of second-generation antiepileptic drugs: pharmacokinetics and clinical aspects. CNS Drugs 2015; 29: 669–681.
    1. Friedman D, French JA. Effects of intermittent levetiracetam dosing in a patient with refractory daily seizures. Neurology 2006; 66: 590–591.
    1. Perucca E, Baltes E, Ledent E. Levetiracetam: absence of pharmacokinetic interactions with other antiepileptic drugs (AEDs) [Abstract] Epilepsia 2000; 41: 150.
    1. May TW, Rambeck B, Juerges U. Serum concentrations of levetiracetam in epileptic patients: the influence of dose and co-medication. Ther Drug Monit 2003; 25: 690–699.
    1. Perucca E, Gidal BE, Baltes E. Effects of antiepileptic comedication on levetiracetam pharmacokinetics: a pooled analysis of data from randomized adjunctive therapy trials. Epilepsy Res 2003; 53: 47–56.
    1. Aldaz A, Alzueta N, Viteri C. Influence of comedication on levetiracetam pharmacokinetics. Ther Drug Monit 2018; 40: 130–134.
    1. Steinhoff BJ, Staack AM, Wisniewski I. Seizure control with antiepileptic drug therapy in 517 consecutive adult outpatients at the Kork Epilepsy Centre. Epileptic Disord 2012; 14: 379–387.
    1. Glauser TA, Pellock JM, Bebin EM, et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia 2002; 43: 518–524.
    1. Sisodiya SM, Sander JW, Patsalos PN. Carbamazepine toxicity during combination therapy with levetiracetam: a pharmacodynamic interaction. Epilepsy Res 2002; 48: 217–219.
    1. Kelly K, Stephen LJ, Brodie MJ. Levetiracetam for people with mental retardation and refractory epilepsy. Epilepsy Behav 2004; 5: 878–883.
    1. Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs) – Part 1: pharmacokinetic and pharmacodynamic interactions between AEDs. Clin Pharmakokinet 2013; 52: 927–966.
    1. Patsalos PN. Drug interactions with the newer antiepileptic drugs (AEDs) – Part 2: pharmacokinetic and pharnacodynamic interactions between AEDs and drugs used to treat non-epilepsy disorders. Clin Pharmakokinet 2013; 52: 1045–1061.
    1. Tomson T, Battino D, Bonizzoni E, et al. Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort study of the EURAP registry. Lancet Neurol 2018; 17: 530–538.
    1. Klein P, Diaz A, Gasalla T, et al. A review of the pharmacology and clinical efficacy of brivaracetam. Clin Pharmacol 2018; 10: 1–22.
    1. Rolan P, Sargentini-Maier ML, Pigeolet E, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after multiple increasing oral doses in healthy men. Br J Clin Pharmacol 2008; 66: 71–75.
    1. Sargentini-Maier ML, Rolan P, Connell J, et al. The pharmacokinetics, CNS pharmacodynamics and adverse event profile of brivaracetam after single increasing oral doses in healthy males. Br J Clin Pharmacol 2007; 63: 680–688.
    1. Nicolas JM, Hannestad J, Holden D, et al. Brivaracetam, a selective high-affinity synaptic vesicle protein 2A (SV2A) ligand with preclinical evidence of high brain permeability and fat onset of action. Epilepsia 2016; 57: 201–209.
    1. Hannestad J, Finnema SJ, Mercier J, et al. Brivaracetam enters the human brain faster than levetiracetam. Epilepsia 2016; 57(Suppl. 2): 128.
    1. Finnema SC, Mercier J, Naganawa M, et al. Brivaracetam enters the brain faster than levetiracetam: a PET study in healthy volunteers. Neurology 2017; 88(Suppl. 16): P6233.
    1. Chanteux H, Kervyn S, Gerin B, et al. In vitro pharmacokinetic profile of brivaracetam reveals low risk of drug-drug interaction and unrestricted brain permeability. Epilepsy Curr 2015; 15(Suppl. 1): 333.
    1. Stockis A, Watanabe S, Rouits E, et al. Brivaracetam single and multiple rising oral dose study in healthy Japanese participants: influence of CYP2C19 genotype. Drug Metab Pharmacokinet 2014; 29: 394–399.
    1. Stockis A, Watanabe S, Scheen AJ, et al. Effect of rifampin on the disposition of brivaracetam in human subjects: further insights into brivaracetam hydrolysis. Drug Metab Dispos 2016; 44: 792–799.
    1. Lacroix B, von Rosenstiel P, Sarrgentini-Maier AL. Population pharmacokinetics of brivaracetam in patients with partial epilepsy. Epilepsia 2007; 48(Suppl. 6): 333.
    1. Stephen LJ, Brodie MJ. Brivaracetam: a novel antiepileptic drug for focal-onset seizures. Ther Adv Neurol Disord 2018; 11: 1–10.
    1. Schoemaker R, Wade JR, Stockis A. Brivaracetam population pharmacokinetics in children with epilepsy aged 1 month to 16 years. Eur J Clin Pharmacol 2017; 73: 727–733.
    1. Sargentini-Maier ML, Sokalski A, Boulanger P, et al. Brivaracetam disposition in renal impairement. J Clin Pharmacol 2012; 52: 1927–1933.
    1. Stockis A, Rolan P. Effect of brivaracetam (400mg/day) in the pharmacokinetics and pharmacodynamics of a combination oral contraceptive in healthy women. J Clin Pharmacol 2013; 53: 1313–1321.
    1. Nicolas JM, Chanteux H, Rosa M, et al. Effect of gemfibrozil on the metabolism of brivaracetam in vitro and in human subjets. Drug Metabol Dispos 2012; 40: 1466–1472.
    1. Otoul C, Stockis A. Evaluation of the pharmacokinetic interaction of brivaracetam on other antiepileptic drugs in adults with partial-onset seizures. Poster presented at American Epilepsy Society 69th Annual meeting, December 4–8, 2015, Philadelphia, PA.
    1. Stockis A, Chanteux H, Rosa M, et al. Brivaracetam and carbamazepine interaction in healthy subjects and in vitro. Epilepsy Res 2015; 113: 19–27.
    1. Brodie MJ, Fakhoury T, McDonough B, et al. Brivaracetam-induced elevation of carbamazepine epoxide levels: a post-hoc analysis from the clinical development program. Epilepsy Res 2018; 145: 55–62.
    1. Steinhoff BJ, Bacher M, Bucurenciu I, et al. Real-life experience with brivaracetam in 101 patients with difficult-to-treat epilepsy – a monocenter survey. Seizure 2017; 48: 11–14.
    1. Klotz KA, Hirsch M, Heers M, et al. Effects of cannabidiol on brivaracetam plasma levels. Epilepsia 2019; 60: e74–e77.
    1. Stockis A, Watanabe S, Fauchoux N. Interaction between brivaracetam (100mg/day) and a combination oral contraceptive: a randomized, double-blind, placebo-controlled study. Epilepsia 2014; 55: e27–e31.
    1. Stockis A, Sargentini-Maier ML, Horsmans Y. Brivaracetam disposition in mild to severe hepatic impairment. J Clin Pharmacol 2013; 53: 633–641.
    1. Steinig I, von Podewils F, Möddel G, et al. Postmarketing experience with brivaracetam in the treatment of epilepsies: a multicenter cohort study from Germany. Epilepsia 2017; 58: 1208–1216.
    1. Klitgaard H, Matagne A, Gobert J, et al. Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy. Eur J Pharmacol 1998; 353: 191–206.
    1. Noyer M, Gillard M, Matagne A, et al. The novel antiepileptic drug levetiracetam (ucb L059) appears to act via a specific binding site in CNS membranes. Eur J Pharmacol 1995; 286: 137–146.
    1. Lynch BA, Lambeng N, Nocka K, et al. The synaptic vesicle protein SV2A is the binding site for the antiepileptic drug levetiracetam. Proc Natl Acad Sci USA 2004; 101: 9861–9866.
    1. Kaminski RM, Gillard M, Leclercq K, et al. Proepileptic phenotype of SV2A-deficient mice is associated with reduced anticonvulsant efficacy of levetiracetam. Epilepsia 2009; 50: 1729–1740.
    1. Kaminski RM, Matagne A, Leclercq K, et al. SV2A protein is a broad-spectrum anticonvulsant target: functional correlation between protein binding and seizure protection in models of both partial and generalized epilepsy. Neuropharmacology 2008; 54: 715–720.
    1. Kaminski RM, Gillard M, Kiltgaard H. Targeting SV2A for discovery of antiepileptic drugs. In: Noebels JL, Avoli M, Rogawski MA, et al. (eds) Jasper’s Basic Mechanisms of the Epilepsies. 4th ed. Bethesda: National Center for Biotechnology Information, 2012: 1–12.
    1. Niespodziany I, Klitgaard H, Margineanu DG. Levetiracetam inhibits the high-voltage-activated Ca(2+) current in pyramidal neurons of rat hippocampal slices. Neurosci Lett 2001; 306: 5–8.
    1. Lukayanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia 2002; 43: 9–18.
    1. Lyseng-Williamson KA. Spotlight on levetiracetam in epilepsy. CNS Drugs 2011; 25: 901–905.
    1. Vogl C, Mochida S, Wolff C, et al. The synaptic vesicle glycoprotein 2A ligand levetiracetam inhibits presynaptic Ca2+ channels through an intracellular pathway. Mol Pharmacol 2012; 82: 199–208.
    1. Detrait E, Lecelrcq K, Matagne A, et al. Protective activity of brivaracetam in the 6Hz model of partial epilepsy: comparison with levetiracetam and older antiepileptic drugs. Epilepsia 2008; 49(Suppl. 7): 1252.
    1. Kenda BM, Matagne AC, Talaga PE, et al. Discovery of 4-substituted pyrrolidone butanamides as new agents with significant antiepileptic activity. J Med Chem 2004; 47: 530–549.
    1. Matagne A, Margineanu DG, Kenda B, et al. Anticonvulsive and anti-epileptic properties of brivaracetam (UCB 34714), a high-affinity ligand for the synaptic vesicle protein SV2A. Br J Pharmacol 2008; 154: 1662–1671.
    1. Tai KK, Truong DD. Brivaracetam is superior to levetiracetam in a rat model of post-hypoxic myoclonus. J Neural Transm 2007; 114: 1547–1551.
    1. Niquet N, Suchomelova L, Thompson K, et al. Acute and long-term effects of brivaracetam and brivaracetam-diazepam combinations in an experimental model of status epilepticus. Epilepsia 2017; 58: 1199–1207.
    1. Gillard M, Fuks B, Leclercq K, et al. Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties. Eur J Pharmacol 2011; 664: 36–44.
    1. Wood MD, Sands ZA, Vanderplas C, et al. Further evidence for a differential interaction of brivaracetam and levetiracetam with the synaptic vesicle 2A protein. Epilepsia 2018; 59: e147–e151.
    1. Kasteleijn-Nolst Trenité DG, Genton P, Parain D, et al. Evaluation of brivaracetam, a novel SV2A ligand, in the photosensitivity model. Neurology 2007; 69: 1027–1034.
    1. Shorvon SD, Löwenthal A, Janz D, et al. Multicenter double-blind, randomized, placebo-controlled trial of levetiracetam as add-on therapy in patients with refractory partial seizures. Epilepsia 2000; 41: 1179–1186.
    1. Cereghino JJ, Biton V, Abou-Khalil B, et al. Levetiracetam for partial seizures: results of a double-blind, randomized clinical trial. Neurology 2000; 55: 236–242.
    1. Ben-Menachem E, Falter U. Efficacy and tolerability of levetiracetam 3000mg/d in patients with refractory partial seizures: a multicenter, double-blind, responder-selected study evaluating monotherapy. European levetiracetam study group. Epilepsia 2000; 41: 1276–1283.
    1. Betts T, Waegemans T, Crawford P. A multicenter, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000mg daily and 4000mg daily, without titration in patients with refractory epilepsy. Seizure 2000; 9: 80–87.
    1. Brodie MJ, Perucca E, Ryvlin P, et al. Comparison of levetiracetam and controlled-release carbamazepine in newly diagnosed epilepsy. Neurology 2007; 68: 402–408.
    1. Werhahn KJ, Trinka E, Dobesberger J, et al. A randomized, double-blind comparison of antiepileptic drug treatment in the elderly with new-onset focal epilepsy. Epilepsia 52015; 6: 450–459.
    1. Berkovic SF, Knowlton RC, Leroy RF, et al. Placebo-controlled study of levetiracetam in idiopathic generalized epilepsy. Neurology 2007; 69: 1751–1760.
    1. Noachtar S, Andermann E, Meyvisch P, et al. Levetiracetam for the treatment of idiopathic generalized epilepsy with myoclonic seizures. Neurology 2008; 70: 607–616.
    1. French JA, Costantini C, Brodsky A, et al. Adjunctive brivaracetam for refractory partial-onset seizures: a randomized, controlled trial. Neurology 2010; 75: 519–525.
    1. Van Paesschen W, Hirsch E, Johnson M, et al. Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: a phase IIb, randomized, controlled trial. Epilepsia 2013; 54: 89–97.
    1. Biton V, Berkovic SF, Abou-Khalil B, et al. Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial. Epilepsia 2014; 55: 57–66.
    1. Ryvlin P, Werhahn KJ, Blaszczyk B, et al. Adjunctive brivaracetam in adults with uncontrolled focal epilepsy: results from a doubleblind, randomized, placebo-controlled trial. Epilepsia 2014; 55: 47–56.
    1. Kwan P, Trinka E, Van Paesschen W, et al. Adjunctive brivaracetam for uncontrolled focal and generalized epilepsies: results of a phase III, double-blind, randomized, placebo-controlled, flexible-dose trial. Epilepsia 2014; 55: 38–46.
    1. Klein P, Schiemann J, Sperling MR, et al. A randomized, double-blind, placebo- controlled, multicenter, parallel-group study to evaluate the efficacy and safety of adjunctive brivaracetam in adult patients with uncontrolled partial-onset seizures. Epilepsia 2015; 56: 1890–1898.
    1. Privitera M. Efficacy of levetiracetam: a review of three pivotal clinical trials. Epilepsia 2001; 42(Suppl. 4): 31–35.
    1. Shorvon SD, van Rijcksevorsel KJ. A new antiepileptic drug. J Neurol Neurosurg Psychiatry 2002; 72: 426–429.
    1. Meencke HJ, Buyle S. Assessment of a dose-response relationship of levetiracetam. Eur J Neurol 2006; 13: 942–946.
    1. Rhee SJ, Shin JW, Lee S, et al. Population pharmacokinetics and dose-response relationship of levetiracetam in adult patients with epilepsy. Epilepsy Res 2017; 132: 8–14.
    1. Krakow K, Walker M, Otoul C, et al. Long-term continuation of levetiracetam in patients with refractory epilepsy. Neurology 2001; 56: 1772–1774.
    1. Bauer J, Ben-Menachem E, Krämer G, et al. Levetiracetam: a long-term follow-up study of efficacy and safety. Acta Neurol Scand 2006; 114: 169–176.
    1. Morrell MJ, Leppik I, French J, et al. The KEEPER trial: levetiracetam adjunctive treatment of partial-onset seizures in an open-label community based study. Epilepsy Res 2003; 54: 153–161.
    1. Steinhoff BJ, Sommerville ER, Van Paeschen W, et al. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Epilepsy Res 2007; 76: 6–14.
    1. Steinhoff BJ, Sommerville ER, Van Paeschen W, et al. The SKATE study: an open-label community-based study of levetiracetam as add-on therapy for adults with uncontrolled partial epilepsy. Epilepsy Res 2007; 76: 6–14.
    1. Borggrafe I, Bonfert M, Bast T, et al. Levetiracetam vs. sulthiame in benign epilepsy with centrotemporal spikes in childhood: a double-blinded, randomized, controlled trial (German HEAD Study). Eur J Paediatr Neurol 2013; 17: 507–514.
    1. Schubert-Bast S, Willems LM, Kurlemann G, et al. Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents. Epilepsy Behav 2018; 89: 89–93.
    1. Hirsch M, Hintz M, Specht A, et al. Tolerability, efficacy and retention rate of brivaracetam in patients previously treated with levetiracetam: a monocenter retrospective analysis. Seizure 2018; 61: 98–103.
    1. Villanueva V, Lopez-González FJ, Mauri JA, et al. BRIVA-LIFE – A multicenter retrospective study of the long-term use of brivaracetam in clinical practice. Acta Neurol Scand 2019; 139: 360–368.
    1. Arnold S, Badalamenti V, Diaz A, et al. Conversion to brivaracetam monotherapy for the treatment of patients with focal seizures: two double-blind, randomized, multicenter, historical control, phase III studies. Epilepsy Res 2018; 141: 73–82.
    1. Zahnert F, Krause K, Immisch I, et al. Brivaracetam in the treatment of patients with epilepsy – first clinical experiences. Front Neurol 2018; 9: 38.
    1. Crest C, Dupont S, Leguern E, et al. Levetiracetam in progressive myoclonic epilepsy: an exploratory study in 9 patients. Neurology 2004; 62: 640–643.
    1. Krauss GL, Betts T, Abou-Khalil B, et al. Levetiracetam treatment of idiopathic generalized epilepsy. Seizure 2003; 12: 617–620.
    1. Kumar SP, Smith PE. Levetiracetam as add-on therapy in generalized epilepsies. Seizure 2004; 13: 475–477.
    1. Maggauda A, Gelisse P, Genton P. Antimyoclonic effect of levetiracetam in 13 patients with Unverricht-Lundborg disease: clinical observations. Epilepsia 2004; 45: 678–681.
    1. Delanty N, Jones J, Tonner F. Adjunctive levetiracetam in children, adolescents and adults with primary generalized seizures: open-label, noncomparative, multicenter, long-term follow-up study. Epilepsia 2012; 63: 111–119.
    1. Rosenfeld WE, Benbadis S, Edrich P, et al. Levetiracetam as add-on therapy for idiopathic generalized epilepsy syndromes with onset during adolescence: analysis of two randomized, double-blind, placebo-controlled studies. Epilepsy Res 2009; 85: 72–80.
    1. Rosenow F, Schade-Brittinger C, Burchardi N, et al. The LaLiMO trial: lamotrigine compared with levetiracetam in the initial 26 weeks of monotherapy for focal and generalized epilepsy – an open-label, prospective, randomized controlled multicenter study. J Neurol Neurosurg Psychiatry 2012; 83: 1093–1098.
    1. Trinka E, Marson AG, Van Paesschen W, et al. KOMET: an unblended, randomized, two-parallel-group, stratified trial comparing the effectiveness of levetiracetam with controlled-release carbamazepine and extended-release sodium valproate as monotherapy in patients with newly diagnosed epilepsy. J Neurol Neurosurg Psychiatry 2013; 84: 1138–1147.
    1. Fattore C, Boniver C, Capovilla G, et al. A multicenter, randomized, placebo-controlled trial of levetiracetam in children and adolescents with newly diagnosed absence epilepsy. Epilepsia 2011; 52: 802–809.
    1. Steinhoff BJ, Kurth C, Dennig D. Levetiracetam in generalized epileptogenesis in adults. Practical experience with its off-label use. Z Epileptol 2013; 25: 118–124.
    1. Strzelczyk A, Kay L, Bauer S, et al. Use of brivaracetam in genetic epilepsies and for acute intravenous treatment of absence status epilepticus. Epilepsia 2018; 59: 1549–1556.
    1. Kälviäinen R, Genton P, Andermann E, et al. Brivaracetam in Unverricht-Lundborg disease (EPM1): results from two randomized, double-blind, placebo-controlled studies. Epilepsia 2016; 57: 210–221.
    1. Ferlazzo E, Russo E, Mumoli L, et al. Profile of brivaracetam and its potential in the treatment of epilepsy. Neuropsychiatr Dis Treat 2015; 11: 2967–2973.
    1. Willems LM, Bertsche A, Bösebeck F, et al. Efficacy, retention, and tolerability of brivaracetam in patients with epileptic encephalopathies: a multicenter cohort study from Germany. Front Neurol 2018; 9: 569.
    1. Brigo F, Kalss S, Trinka E. Phenytoin, valproate, levetiracetam and lacosamide in status epilepticus. Which is first choice and when should it be used? Z Epileptol 2018; 31: 250–255.
    1. Zelano J, Kumlien E. Levetiracetam as alternative stage two antiepileptic drug in status epilepticus: a systematic review. Seizure 2012; 21: 233–236.
    1. Brigo F, Bragazzi N, Nardone R, et al. Direct and indirect comparison meta-analysis of levetiracetam versus phenytoin or valproate for convulsive status epilepticus. Epilepsy Behav 2016; 64: 110–115.
    1. Navarro V, Dagron C, Elie C, et al. Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppra): a randomized, double-blind, phase 3 trial. Lancet Neurol 2016; 15: 47–55.
    1. Mundlamuri RC, Sinha S, Subbakrishna DK, et al. Management of generalized convulsive status epilepticus (SE): a prospective randomized controlled study of combined treatment with intravenous lorazepam with either phenytoin, sodium valproate or levetiracetam – pilot study. Epilepsy Res 2015; 114: 52–58.
    1. Gujjar AR, Nandhagopal R, Jacob PC, et al. Intravenous levetiracetam vs phenytoin for status epilepticus and cluster seizures: a prospective, randomized study. Seizure 2017; 49: 8–12.
    1. Chakravarthi S, Goyal MK, Modi M, et al. Levetiracetam versus phenytoin in management of status epilepticus. J Clin Neurosci 2015; 22: 959–963.
    1. Nene D, Mundlamuri RC, Satishchandra P, et al. Comparing the efficacy of sodium valproate and levetiracetam following initial lorazepam in elderly patients with generalized convulsive status epilepticus (GCSE): a prospective randomized controlled pilot study. Seizure 2019; 65: 111–117.
    1. Yasiry Z, Shorvon SD. The relative effectiveness of five antiepileptic drugs in treatment of benzodiazepine-resistant convulsive status epilepticus: a meta-analysis of published studies. Seizure 2014; 23: 167–174.
    1. Kellinghaus C, Rosetti AO, Trinka E, et al. Factors predicting cessation of status epilepticus in clinical practice: Data from a prospective observational registry (SENSE). Ann Neurol 2019; 85: 421–432.
    1. Strzelczyk A, Steinig I, Willems LM, et al. Treatment of refractory and super-refractory status epilepticus with brivaracetam: a cohort study from two German university hospitals. Epilepsy Behav 2017; 70: 177–181.
    1. Kalss G, Rohracher A, Leitinger M, et al. Intravenous brivaracetam in status epilepticus: a retrospective single-center study. Epilepsia 2018; 59(Suppl. 2): 228–233.
    1. Arroyo S, Crawford P. Safety profile of levetiracetam. Epileptic Disord 2003; 5: 57–63.
    1. Buck ML. Levetiracetam for the treatment of partial seizures. Pediatric Pharmacoth 2002; 8: 1–5.
    1. Harden CL. Safety profile of levetiracetam. Epilepsia 2001; 42(Suppl. 4): 36–49.
    1. Welty TE, Gidal BE, Ficker DM, et al. Levetiracetam: a different approach to the pharmacotherapy of epilepsy. Ann Pharmacother 2002; 36: 296–304.
    1. Brodie MJ, Besag F, Ettinger AB, et al. Epilepsy, antiepileptic drugs, and aggression: an evidence-base review. Pharmacol Rev 2016; 68: 563–602.
    1. Labiner DM, Ettinger AB, Fakhoury TA, et al. Effects of lamotrigine compared with levetiracetam on anger, hostility, and total mood in patients with partial epilepsy. Epilepsia 2009; 50: 434–442.
    1. Lee JJ, Song HS, Hwang YH, et al. Psychiatric symptoms and quality of life in patients with drug-refractory epilepsy receiving adjunctive levetiracetam therapy. J Clin Neurol 2011; 7: 128–136.
    1. Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 2007; 16: 296–304.
    1. Kang BS, Moon HJ, Kim YS, et al. The long-term efficacy and safety of levetiracetam in a tertiary epilepsy center. Epileptic Disord 2013; 15: 302–310.
    1. D’Souza J, Johnson M, Borghs S. Meta-analysis of non-psychotic behavioral treatment-emergent adverse events in brivaracetam and levetiracetam development programs. Epilepsia 2012; 53(Suppl. 5): 118: abstract P402.
    1. Yates SL, Fakhoury T, Liang W, et al. An open-label, prospective, exploratory study of patients with epilepsy switching from levetiracetam to brivaracetam. Epilepsy Behav 2015; 52: 165–168.
    1. Theochari E, Cock H, Lozsadi D, et al. Brivaracetam in adults with drug-resistant epilepsy and psychiatric comorbidities. Epilepsy Behav 2019; 90: 129–131.
    1. Toledo M, Abraira L, Mazuela G, et al. Effect of Brivaracetam on the anger levels of epilepsy patients. A prospective open-labelled controlled study. Seizure 2019; 69: 198–203.
    1. Zhang L, Li S, Li H, et al. Levetiracetam vs. brivaracetam for adults with refractory focal seizures: a meta-analysis and indirect comparison. Seizure 2016; 39: 28–33.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅